Literature DB >> 33219328

Hepatocyte-specific deletion of XBP1 sensitizes mice to liver injury through hyperactivation of IRE1α.

Caroline C Duwaerts1,2, Kevin Siao1,2, Russell K Soon1,2,3, Chris Her1,2, Takao Iwawaki4, Kenji Kohno5, Aras N Mattis2,6, Jacquelyn J Maher7,8.   

Abstract

X-box binding protein-1 (XBP1) is a transcription factor that plays a central role in controlling cellular responses to endoplasmic reticulum (ER) stress. Under stress conditions, the transcriptionally active form of XBP1 is generated via splicing of Xbp1 mRNA by the ER-resident protein inositol-requiring enzyme-1 (IRE1α). Genetic deletion of XBP1 has multiple consequences: some resulting from the loss of the transcription factor per se, and others related to compensatory activation of IRE1α. The objective of the current study was to investigate the effects of XBP1 deletion in adult mouse liver and determine to what extent they are direct or indirect. XBP1 was deleted from hepatocytes in adult Xbp1fl/fl mice using AAV8-Transthyretin-Cre (Xbp1Δhep). Xbp1Δhep mice exhibited no liver disease at baseline, but developed acute biochemical and histologic liver injury in response to a dietary challenge with fructose for 4 weeks. Fructose-mediated liver injury in Xbp1Δhep mice coincided with heightened IRE1α activity, as demonstrated by Xbp1 mRNA splicing, JNK activation, and regulated IRE1α-dependent RNA decay (RIDD). Activation of eIF2α was also evident, with associated up-regulation of the pro-apoptotic molecules CHOP, BIM, and PUMA. To determine whether the adverse consequences of liver-specific XBP1 deletion were due to XBP1 loss or heightened IRE1α activity, we repeated a fructose challenge in mice with liver-specific deletion of both XBP1 and IRE1α (Xbp1Δhep;Ire1aΔhep). Xbp1Δhep;Ire1aΔhep mice were protected from fructose-mediated liver injury and failed to exhibit any of the signs of ER stress seen in mice lacking XBP1 alone. The protective effect of IRE1α deletion persisted even with long-term exposure to fructose. Xbp1Δhep mice developed liver fibrosis at 16 weeks, but Xbp1Δhep;Ire1aΔhep mice did not. Overall, the results indicate that the deleterious effects of hepatocyte-specific XBP1 deletion are due primarily to hyperactivation of IRE1α. They support further exploration of IRE1α as a contributor to acute and chronic liver diseases.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33219328      PMCID: PMC8166833          DOI: 10.1038/s41418-020-00671-1

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  5 in total

Review 1.  Emerging therapeutic potential of adeno-associated virus-mediated gene therapy in liver fibrosis.

Authors:  Fang-Tian Bu; Peng-Cheng Jia; Yan Zhu; Ya-Ru Yang; Hong-Wu Meng; Yi-Hui Bi; Cheng Huang; Jun Li
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-22       Impact factor: 5.849

2.  Mechanisms of liver injury in high fat sugar diet fed mice that lack hepatocyte X-box binding protein 1.

Authors:  Xiaoying Liu; Sarah A Taylor; Kyle D Gromer; Danny Zhang; Susan C Hubchak; Brian E LeCuyer; Takao Iwawaki; Zengdun Shi; Don C Rockey; Richard M Green
Journal:  PLoS One       Date:  2022-01-14       Impact factor: 3.240

Review 3.  ER Disposal Pathways in Chronic Liver Disease: Protective, Pathogenic, and Potential Therapeutic Targets.

Authors:  Caroline C Duwaerts; Jessica L Maiers
Journal:  Front Mol Biosci       Date:  2022-01-31

4.  The Role of STING in Liver Injury Is Both Stimulus- and Time-Dependent.

Authors:  Kevin Siao; Dounia Le Guillou; Jacquelyn J Maher; Caroline C Duwaerts
Journal:  Nutrients       Date:  2022-09-28       Impact factor: 6.706

5.  Coordinated signaling of activating transcription factor 6α and inositol-requiring enzyme 1α regulates hepatic stellate cell-mediated fibrogenesis in mice.

Authors:  Fei Xue; Jianwen Lu; Samuel C Buchl; Liankang Sun; Vijay H Shah; Harmeet Malhi; Jessica L Maiers
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-03-17       Impact factor: 4.052

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.